Perspective Therapeutics (CATX) Q4 2025 earnings summary

Executive summary

• Lead program VMT-a-NET in neuroendocrine tumors shows favorable tolerability and durable disease control, with deepening tumor responses over longer follow-up, as reported at ASCO-GI 2026.

• All three clinical programs (VMT-a-NET, VMT01, PSV359) are advancing, with updates expected at medical conferences throughout 2026.

• Cash and investments of $145M at year-end 2025, plus $164M from a February 2026 equity offering, are expected to fund operations into late 2027.

Financial highlights

• Cash, cash equivalents, and short-term investments were $145M as of December 31, 2025, down from $227M at year-end 2024.

• Net loss for 2025 was $103.1M ($1.40 per share), compared to $79.3M ($1.23 per share) in 2024.

• Research and development expenses rose 102% to $84.2M, driven by increased clinical activity and personnel costs.

• General and administrative expenses increased 14% to $30.2M.

• Grant revenue was $0.9M for 2025, down from $1.5M in 2024.

Outlook and guidance

• Data readouts from all clinical programs are expected throughout 2026, with regulatory engagement planned.

• Cash runway is projected to support planned milestones and operations into late 2027.